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was tolerability related to the number of withdrawals patients in each study, due 
to the presence of adverse events or treatment failure. The analyses were per-
formed using software Addis (v.1.16.5) and RevMan (5.1). Results: A total of 979 
documents were initially identified and 11 of them met the selection criteria to 
meta-analysis. No significant differences were observed between the number of 
withdrawals patients due adverse events in any meta-analysis of control ver-
sus intervention. The odds ratio ranged from 0.68 (CI 032-1.45) to placebo versus 
asenapine, 1.37 (CI 0.29-1.33) to placebo versus iloperidone and 0,71 (CI 0,36-1,41) 
to placebo versus lurasidone. However, all drugs were superior to their respective 
controls for the outcome of number of withdrawals by treatment failure, with 
odds ratio between 1.70 (CI 1.21-2.39) and 2.36 (CI 1.36-4.07). These results suggest 
that there is a higher effectiveness among patients for the treatment interven-
tion that should be evaluated through clinical responses. Heterogeneity between 
studies (evaluated by I2 values) were low or moderate, not superior than 39,5% 
in any meta-analysis. ConClusions: Information and knowledge reunion and 
confrontation on the tolerability profile of a particular drug allows safer decisions 
over the therapeutic approach, focused on patient’s interest which directly reflects 
on treatment follow-through and therapy effectiveness. In this study, we report 
evidence on asenapine, iloperidone and lurasidone greater tolerability profile 
compared to placebo in schizophrenia treatment.
MENTAL HEALTH – Cost Studies
PMH5
LAgrANgE METHod for BudgET oPTiMizATioN ANALySiS iN rESourCE 
ALLoCATioN for ANTiPSyCHoTiC THErAPiES iN CoLoMBiA
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objeCtives: To simulate the optimal budget allocation for first line antipsychotic 
medications in schizophrenia which minimize relapses. Methods: From the 
health system perspective, a Lagrange budget optimization analysis was per-
formed with the SOLVER application in order to estimate the efficient market 
share of first line antipsychotics (oral, depot and Long Acting Injectable - LAI). 
The following parameters were gathered and validated in five psychiatric institu-
tions: target population, current market share, adherence to the treatment, risk 
of relapse, and the usage of outpatient and inpatient care resources. The tariffs 
were taken from official and institutional sources. The time frame was one year. 
Two scenarios were compared: the current and the optimum. Results: Current 
scenario: assuming a budget constraint of USD 250,000, a target population of 
381 patients and a baseline market share (oral 95.7%, depot 2.3% and LAI 2.0%), 
150 relapses were avoided (savings of USD 320,086). With the Optimum scenario 
market share [oral 83.0%, depot 4.0% and LAI 13.0%], 208 relapses were avoided 
[savings of USD 445,986]. ConClusions: Assuming a fixed budget for first line 
antipsychotic treatments, increasing the usage of LAI enable a budget optimiza-
tion and relapses minimization.
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objeCtives: To quantify the cost of schizophrenia relapse in Argentina from the 
perspective of the public and third party payer. Schizophrenia is a chronic, severe, 
and disabling mental disorder that significantly affects a person’s thought processes 
and emotional responsiveness. Due to the debilitating nature of the illness, people 
with schizophrenia have a relatively high utilization rate of health care and mental 
health services. Although there is currently no cure for schizophrenia, treatment 
is available to manage the symptoms and reduce the risk of relapse. However, poor 
adherence to treatment remains a significant issue with evidence showing that up 
to 60% of patients are partially or totally non-adherent to their prescribed oral treat-
ments. Methods: A cost of disease study was performed including direct, indi-
rect and transference costs of relapses in schizophrenia. Bottom-up and top down 
methodologies were used to obtain direct costs of health care services consumed by 
this population. Validation of clinical criteria took place with local KOLs. Burden of 
disease was calculated using Disability Adjusted Life Years (DALY) supported by the 
CEPAL. The impact on the local economy was also included by obtaining transfer-
ence costs. Results: This study estimated that there were 415,870 patients with 
schizophrenia, from which 87.333 experienced some episode of relapse in Argentina. 
This corresponds to 21% of patients with schizophrenia. The total potential avoid-
able direct healthcare cost of relapse, total indirect cost over a 12 month period, and 
percentage of people not employed due to relapsing disease were calculated and 
will be presented in the publication. ConClusions: Argentinian decision makers 
in health can largely benefit by controlling relapses for these types of patients. 
This study is one of the first approaches at quantifying the impact of the disease 
and its relapse.
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CoSTo dE ENfErMEdAdES MENTALES PrEvALENTES EN PErú
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objeCtivos: Estimar los costos de enfermedades mentales prevalentes (EMP) 
en los establecimientos del Ministerio de Salud del Perú. MetodologíAs: Se 
realizó una evaluación económica parcial de tipo costo de enfermedad (CE). La 
población de estudio fue una cohorte hipotética de pacientes afiliada al Seguro 
Público de Salud (Seguro Integral de Salud) en el Perú. Los costos se estimaron 
symptoms (PCC -0.25 for positive symptoms and -0.29 for negative symptoms; 
p< 0.001). Improvement in negative symptoms was highly correlated to improve-
ment in QoL (PCC 0.33; p< 0.0001). The regression model analysing the influence 
of both positive and negative symptoms on QoL at baseline was confirmative and 
showed a greater beta coefficient (higher influence) for negative symptoms com-
pared with positive symptoms [(3.9 (se 0.14) versus 2.9 (se 0.13)]. Another model 
found that patients with greater negative symptoms at baseline experienced lower 
improvement in QoL (beta coefficient -0.81; se 0.11; p< 0.001). ConClusions: In 
patients with schizophrenia negative symptoms seem to have a larger influence 
onself-perceived QoL than positive symptoms. Improvement in negative symp-
toms is highly associated with improvements in QoL.
PMH2
AvALiAção dE TECNoLogiAS No TrATAMENTo dA dEPrESSão MAior: 
ovErviEw SoBrE A EfiCáCiA E SEgurANçA dA duLoxETiNA, vENLAfAxiNA E 
TrAzodoNA CoMPArAdoS À fLuoxETiNA
Marra LP1, Silva SN1, Costa Jd2, Acurcio FA1, Guerra-Júnior AA1
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objetivos: O objetivo desse estudo é revisar a evidência científica disponível sobre 
a eficácia e segurança dos antidepressivos de segunda geração duloxetina, venla-
faxina e trazodona em comparação à fluoxetina para o tratamento do Transtorno 
Depressivo Maior (TDM) em adultos. Métodos: Buscaram-se revisões sistemáticas 
(RS) de ensaios clínicos que comparassem a eficácia e segurança dos medicamentos 
duloxetina, venlafaxina e trazodona frente à fluoxetina para o tratamento do TDM nas 
bases de dados PUBMED, LILACS, CENTRAL e CRD. A avaliação da qualidade da evidên-
cia foi realizada por meio da ferramenta GRADE. Avaliações de Tecnologias de Saúde 
(ATS) e guias terapêuticos foram pesquisados em sites de agências nacionais e inter-
nacionais. O custo mensal do tratamento foi calculado para aquisições por compras 
públicas. ResultAdos: Foram incluídas 12 RS com meta-análise. Em geral os estudos 
apresentaram baixa qualidade metodológica. Nove estudos apontaram superioridade 
do tratamento com venlafaxina frente à fluoxetina na redução de 50% dos sintomas. 
A razão de resposta (RR ou OR) entre os grupos venlafaxina e fluoxetina variou entre 
1,12 e 1,36. Em geral, a taxa de abandono e a incidência de eventos adversos foram 
maiores para os grupos venlafaxina e duloxetina, comparados ao grupo fluoxetina. As 
4 ATS encontradas concluíram que os antidepressivos de segunda geração possuíam 
eficácia comparável à da fluoxetina, com maior custo associado. O tratamento com a 
fluoxetina corresponde ao menor valor. ConClusões: Verificou-se baixa qualidade 
da evidência dos resultados, menor custo de tratamento com o medicamento fluox-
etina e recomendações das Agências de ATS e guias terapêuticos quanto a eficácia 
comparável entre os antidepressivos e indicação da fluoxetina no diagnóstico inicial 
do TDM. Recomenda-se que a fluoxetina seja o medicamento de primeira escolha 
para o tratamento do TDM em pacientes adultos e em caso de resposta inadequada, 
a venlafaxina poderia ser utilizada como segunda escolha.
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objeCtives: To evaluate the efficacy and safety of methylphenidate com-
pared to other pharmacological alternatives or placebo in the treatment of 
ADHD. Methods: Health technology assessments (HTA), randomized clinical 
trials (RCT) or systematic reviews (SR) of RCT were systematically researched. 
Inclusion criteria were placebo or pharmacological intervention as comparators, 
and children or adolescents as population. Studies about different dosis or pres-
entations of methylphenidate were also selected. Results: One ECR, four SR and 
two HTA were selected comparing methylphenidate to placebo, atomoxetine, bus-
pirone, dexamphetamine. Methylphenidate was superior to placebo in the index of 
hyperactivity detected by parents and teachers, behavior during the execution of 
tasks, productivity in classroom and in precision of the activities. Response rates to 
treatment and abandonment were better as compared to atomoxetine. Compared 
to buspirone, methylphenidate was shown to be more effective in reducing the 
symptoms of ADHD. Benefits of methylphenidate on dexamphetamine are incon-
clusive. Low dose methylphenidate was superior to high dose in behavior improve-
ment on the execution of tasks. There was no difference between long and short 
acting presentations. Regarding security: anorexia, insomnia, migraines, stomach 
pain and dizziness were often associated with methylphenidate. ConClusions: 
Primary studies showed methodological limitations such as low quality, short fol-
low up and low capacity of generalization. The evaluation of the results should be 
cautious. It is necessary to find a balance between benefits and risks before start-
ing the administration of methylphenidate in children and adolescents, especially 
in long-term treatments.
PMH4
CoMPArATivE ToLErABiLiTy of NEw ANTiPSyCHoTiC drugS iN 
SCHizoPHrENiA: A SySTEMATiC rEviEw ANd META-ANALySiS
Tonin FS, Piazza T, Wiens A, Pontarolo R
Universidade Federal do Paraná, Curitiba, Brazil
objeCtives: Evaluate the tolerability of three antipsychotic drugs – asenapine, 
iloperidone and lurasidone – in the treatment of schizophrenia. Methods: An 
eletronic search was performed in Medline (Pubmed), Cochrane Library, Scopus, 
Science Direct and Scielo. A systematic review and meta-analysis of randomized 
controlled trials (RCTs) comparing the use of any of the above-mentioned drugs 
versusplacebo in schizophrenia was realized. Publications available in English, 
Portuguese, Spanish, French and German were evaluated. The main outcome 
A838  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 8 0 5 – A 8 8 1  
PMH10
HEALTHCArE ACCESS diffErENCES BETwEEN PuBLiC ANd PrivATE 
iNSurANCE CovErAgE AMoNg PATiENTS wiTH dEPrESSioN iN BrAziL
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objeCtives: Public and private healthcare systems in Brazil differ in focus and 
regulations for disease management, especially mental health. The aim of this 
study was to assess differences between privately and publicly insured patients in 
access to care, as well as differences in mental health, work productivity impair-
ment, and healthcare resource utilization among patients diagnosed with depres-
sion. Methods: The 2014 Brazil National Health and Wellness Survey (N= 9,082), 
a self-reported, cross-sectional survey representative of the adult population, 
provided data. Access outcomes included physician diagnosis of depression, 
visits to psychiatrists, and visits to psychologists in the past six months. Other 
outcomes included work impairment due to health using the Work Productivity 
and Activity Impairment questionnaire and depression severity according to the 
Patient Health Questionnaire. Patients with private insurance were compared to 
patients with only public insurance with chi-square tests; generalized linear mod-
els were used to adjust outcomes for covariates. Results: Overall, 11% (n= 990) 
of the sample reported a depression diagnosis. Diagnosis was more common 
among those with private than public insurance (12.5% vs. 9.3%, p< 0.001), a pat-
tern that remained after controlling for covariates (OR= 1.4, p< 0.001). Visiting a 
psychiatrist (OR= 1.7) or a psychologist (OR= 1.8) was also more common with 
private insurance (both p< 0.001). Among those diagnosed with depression, sever-
ity was lower among those with private insurance (mean 10.8 vs. 11.9, p= 0.026). 
Employed patients with depression with private insurance missed more work 
due to health (14.3% vs. 8.0%, p< 0.01), while the levels of health-related impair-
ment while at work, overall work impairment, and activity impairment were not 
significantly different. ConClusions: Private insurance appears to be associated 
with more access to depression care as well as less severe depression among 
depression patients. More work missed among privately insured patients warrants 
further study, and may be due to differences not included here, such as type of 
employment.
MENTAL HEALTH – Health Care use & Policy Studies
PMH11
uSo dE rECurSoS MEdiCoS EN LA iNTErvENCioN dE ExAMENES dE 
TAMizAjE y TrATAMiENTo dE PACiENTES CoN ProBLEMAS y TrASTorNoS dE 
SALud MENTAL 2012-2013
Meza J, Gutierrez- Aguado A
UNMSM, Lima, Peru
objeCtivos: Estimar el uso de recursos médicos en la intervención de exámenes 
de tamizaje y tratamiento de pacientes con problemas y trastornos de salud mental 
2012-2013 MetodologíAs: Se utilizó la metodología de uso de recursos médicos 
en referencia al recurso humano, materiales e insumos médicos, medicamentos 
y equipamiento; considerando la asignación presupuestal en la intervención de 
exámenes de tamizaje y tratamiento de pacientes con problemas y trastornos 
de salud mental 2012-2013. en el ámbito de Presupuesto por Resultados (PpR). 
Contrastándose el uso de recursos médicos versus el indicador de desempeño del 
programa: Violencia familiar tomado de la Encuesta de Demografía y salud familiar 
(ENDES) 2012-2013. ResultAdos: El uso de recursos humano en la intervención del 
2012- 2013 aumento de US$ 1,341,478 a US$1,796,384, el material e insumo medico 
disminuyo de US$134,302 a US$70,466, en medicamentos disminuyó de US$54,015 
a US$12,899, en equipos disminuyo de US$40,440 a US$1,126, Para el año 2012 el 
Porcentaje de Mujeres que sufrieron agresión física fue de 12.9, Para el año 2013 
Porcentaje de Mujeres que sufrieron agresión física fue de 12.1 ConClusiones: 
La priorización en el presupuesto del uso de recurso humano en la intervención de 
exámenes de tamizaje y tratamiento de pacientes con problemas y trastornos de 
salud mental 2012-2013 ha tenido buenos resultados por lo que se debe tener mejor 
calidad de gasto en este recurso
PMH12
CoSTS of rELAPSE of SCHizoPHrENiA for CoLoMBiAN HEALTH SySTEM
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Schizophrenia is a chronic, severe, and disabling mental disorder that significantly 
affects a person’s thought processes and emotional responsiveness. People with 
schizophrenia have a relatively high utilization rate of health care and mental 
health services.objeCtives: To quantify the cost of schizophrenia relapse in 
Colombia from the perspective of the third payer. Methods: A cost of disease 
study was performed including direct, indirect and transference costs of relapses 
in schizophrenia. Bottom-up and top down methodologies were used to obtain 
direct costs consumed by this population. Validation of clinical criteria took place 
with local KOLs for epidemiological data and resoureces estimation. Burden of 
disease was calculated using Disability Adjusted Life Years. The impact on the local 
economy was also included by obtaining transference costs. Results: There is an 
estimation of 714,927 people living with schizophrenia in Colombia. The preva-
lence rate is 1.5%. Compared to other chronic conditions, onset of schizophrenia 
typically occurs at between 20 and 30 years. This study estimated that a total of 
150.135 patients experienced some episodes of relapse in 2014. This corresponds 
to 21% of patients with schizophrenia. This study found that the total potential 
avoidable direct healthcare costs of relapse in Colombia were COP$ 145´425.137 
(US$66, 1 million). Total indirect costs were estimated to be COP $ 28.882 million 
(US$ 13.1 million) over a 12 month period. There were 5.540 people not employed 
due to relapse which resulted in a loss of productivity of $COP 27.499 million (US$ 
desde la perspectiva del financiador tomados para el año 2014. La definición de 
los esquemas de manejo clínico (procedimientos médicos y medicamentos para 
el diagnóstico, tratamiento y seguimiento de la enfermedad) provienen de las 
Condiciones Asegurables del Plan Esencial de Aseguramiento en Salud (PEAS). 
Cada esquema de manejo clínico se ha estimado con la metodología de costeo 
estándar. El costo total fue ajustado por factores de oferta, demanda y adheren-
cia. ResultAdos: La cohorte hipotética de pacientes con enfermedades mentales 
prevalentes (EMP) es de 75,584 (Incidencia esquizofrenia: 1%, incidencia de ansie-
dad: 19.5%, incidencia de depresión: 9% e incidencia de alcoholismo: 11.6%). El 
costo total para EMP es de 21,893,108 dólares distribuido según enfermedad para 
esquizofrenia 3,356,030 dólares (15%), ansiedad 2,040,292 dólares (9%); depresión 
12,621,897 dólares (58%) y para alcoholismo 3,874,889 (18%). El costo total corre-
spondiente a prevención es 943,888 dólares (4.3%), diagnóstico 1,771,448 dólares 
(8.1%), tratamiento 15,030,859 dólares (68.7%) y para seguimiento 4,146,913 dólares 
(18.9%). El costo fijo correspondió a 10,160,137 dólares (46.4%) y el costo variable 
a 11,732,971 dólares (53.6%). ConClusiones: El costo anual total para enferme-
dades mentales prevalentes en el país se estimó en 21,893,108 dólares. Este monto 
representa el 91.3% del presupuesto asignado 2015 del Programa Presupuestal 131 
Control de Enfermedades Mentales.
PMH8
EvALuACioN ECoNoMiCA dEL SEguiMiENTo fArMACoTErAPéuTiCo EN 
PACiENTES CoN TrASTorNo AfECTivo BiPoLAr i
Monsalve M, Hincapie García JA, Salazar-Ospina A, Amariles P
Universidad de Antioquia, Medellin, Colombia
objeCtivos: El seguimiento farmacoterapéutico (SFT) es una tecnología en salud, 
en la cual un profesional farmacéutico se responsabiliza de las necesidades del 
paciente para contribuir al logro de mejores resultados farmacoterapéuticos posi-
bles. Propósito para el cual el método Dáder ha sido ampliamente utilizado. El 
objetivo de este estudio fue realizar un análisis costo efectividad del efecto del 
método Dáder de SFT en pacientes con Trastorno Afectivo Bipolar (TAB I), usando 
la perspectiva del tercer pagador en Colombia. MetodologíAs: Análisis de 
costo/efectividad del SFT en pacientes con TAB I, comparado con el tratamiento 
convencional. Perspectiva: tercer pagador en Colombia. Horizonte temporal: 1 
año. Se construyó un árbol de decisión, con las probabilidades de recaída y los 
costos asociados de las dos alternativas evaluadas: la atención convencional y 
la adición del SFT. Los datos de efectividad se tomaron directamente del ensayo 
clínico randomizado EMDADER-TAB-I, específicamente se utilizó como medida 
efectividad la probabilidad de mantener al paciente eutímico durante un año. 
El macrocosteo se realizó con información del mercado y de bases de datos uti-
lizadas como referencia en Colombia. ResultAdos: Los resultados del modelo 
indican que el SFT es una estrategia dominante sobre la atención convencional, 
siendo menos costosa (delta costos directos – 58.35 U$) y más efectiva (delta de 
efectividad 0,1518). Se pueden generar ahorros para el sistema de 396.95 U$ al 
año por paciente con TAB. Se realizaron dos análisis de sensibilidad; el primero 
determinístico de una vía, con el costo del SFT como variable incertidumbre y el 
segundo probabilísticos de todo el modelo. Se confirmó la robustez de los resul-
tados. ConClusiones: El SFT, como tecnología que se adiciona a la atención 
habitual, resultó ser costo efectivo desde la perspectiva del tercer pagador. La dismi-
nución de las recaídas y por ende de las hospitalizaciones ofrece un ahorro para el 
sistema.
MENTAL HEALTH – Patient-reported outcomes & Patient Preference Studies
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iNdividuAL ANd SoCiETAL BurdEN of NoN-AdHErENCE To 
ANTidEPrESSANTS iN BrAziL
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objeCtives: The World Health Organization estimates that depression affects 350 
million people worldwide and is the leading cause of disability. Although effica-
cious and cost-effective treatments are available, non-adherence is common and 
one of the most significant issues for successful treatment. Medication-adherent 
patients have almost three times greater odds for positive outcomes than patients 
with low adherence; poor adherence leads to quality of life decrements, mental 
health deterioration and increased costs, with indirect cost as the major impacting 
cost. Due to a lack of Brazilian data, this study investigates the association between 
adherence and burden of depression in the Brazilian population. Methods: Data 
were from the 2011-2012 Brazil National Health and Wellness Survey (NHWS), 
an internet-based survey from a representative sample of adults stratified by 
age and gender. Out of 24,000 respondents, 2,760 (12%) reported a diagnosis of 
depression and 1,487 (6%) having a prescription medication for depression (Rx). 
Adherent respondents – high/medium adherence on the Morisky Medication 
Adherence Scale (MMAS-4) – were compared to the non-adherent on severity 
(PHQ-9), sociodemographics, health characteristics, health-related quality of life 
(SF-36), work productivity and activity impairment (WPAI) and healthcare resource 
use (physician, hospital and emergency visits). Results: Non-adherent respond-
ents (79%), compared to adherent respondents, were more severe (22% vs. 17% 
with PHQ-9 score ≥ 15); had lower Mental Component Summary (MCS: 33 vs. 36); 
lower health utilities (SF-6D: 0.59 vs. 0.60); higher presenteeism (42 vs. 37); and 
their satisfaction with medication was lower (4.9 vs. 5.3) (All p< 0.05). About 33% 
of both groups were participating in psychotherapy and showed no significant 
difference in Physical Component Summary (PCS); absenteeism; and healthcare 
resource use. ConClusions: In this real-world study for Brazilian patients with 
depression, adherence demonstrated an important relationship on patients’ out-
comes to medication satisfaction and productivity, being an important key to 
successful treatment.
